.Attributes Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of individuals with HER2+ state-of-the-art breast cancer and energetic or even stable mind metastases showed consistent intracranial activity and systemic effectiveness of T-DXd.